Optimizing Patient Care in MIBC with MRD Testing, Real-World Clinical Cases - European Medical Journal

Continue

Optimizing Patient Care in MIBC with MRD Testing, Real-World Clinical Cases

Oncology

This content is funded by Natera.

 

Learn how molecular residual disease (MRD) testing is advancing the care of muscle-invasive bladder cancer (MIBC). Explore how MRD testing, including circulating tumor DNA (ctDNA), enables earlier detection of disease recurrence than traditional imaging, helping clinicians make more informed decisions for their patients.

Learn:

  • The fundamentals of MRD testing: Understand how ctDNA is used to detect recurrence in MIBC.
  • Clinical applications: See examples of how MRD testing is used in clinical practice.
  • Insights from ongoing research: Hear about the latest trials and emerging evidence on ctDNA.
  • Practical guidance: Learn how MRD can be integrated into your own practice.

Faculty

Adam ElNaggar1

Vadim Koshkin1

1. Senior Medical Director of Oncology, Natera, Inc., USA

2. Associate Professor of Medicine, Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco (UCSF), USA

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.